Evacetrapib（ACS/急性冠症候群）：医薬品市場予測及び分析（～2023）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 20
3.1.3 Prognosis 21
3.1.4 Quality of Life 22
3.2 Symptoms 22
4 Disease Management 24
4.1 Treatment Overview 24
5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 31
6 Unmet Need and Opportunity 36
6.1 Overview 36
6.2 Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques 37
6.2.1 Unmet Need 37
6.2.2 Gap Analysis 38
6.2.3 Opportunity 38
6.3 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities 39
6.3.1 Unmet Need 39
6.3.2 Gap Analysis 40
6.3.3 Opportunity 40
6.4 LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients 41
6.4.1 Unmet Need 41
6.4.2 Gap Analysis 43
6.4.3 Opportunity 45
6.5 Antidotes for New Oral Anticoagulants (NOACs) 45
6.5.1 Unmet Need 45
6.5.2 Gap Analysis 46
6.5.3 Opportunity 46
6.6 Blood-Thinning Agents with Significantly Reduced Bleeding Risks 47
6.6.1 Unmet Need 47
6.6.2 Gap Analysis 48
6.6.3 Opportunity 48
7 Pipeline Assessment 50
7.1 Overview 50
7.2 Clinical Trials by Phase and Trial Status 52
7.3 Promising Drugs in Clinical Development 54
8 Evacetrapib 59
8.1 Overview 59
8.2 Efficacy 60
8.3 Safety 61
8.4 Dosing and Formulation 61
8.5 Potential Clinical Positioning 62
8.6 Potential Commercial Positioning 62
8.7 Pricing and Reimbursement 62
8.8 SWOT Analysis 63
8.9 Forecast 63
9 Appendix 65
9.1 Bibliography 65
9.2 Abbreviations 71
9.3 Methodology 75
9.4 Forecasting Methodology 75
9.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 75
9.4.2 Diagnosed Acute Coronary Syndrome Patients 76
9.4.3 Percent Drug-Treated Patients 77
9.4.4 General Pricing Assumptions 77
9.4.5 Generic Erosion 79
9.4.6 Pricing of Pipeline Agents 79
9.5 Physicians and Specialists Included in this Study 80
9.6 About the Authors 83
9.6.1 Author 83
9.6.2 Reviewer 83
9.6.3 Global Head of Healthcare 84
9.7 About GlobalData 85
9.8 Disclaimer 85